SIGNIFICANCE OF THE EXPRESSION OF CD123 AND THEIR CLINICAL IMPACT IN ACUTE MYELOID LEUKEMIA AMONG SUDANESE PATIENTS

Amro .B .E . Bashir; Tarig A.M. Hamid; Nadia M. Madani; Babeker Ahmed  Mohammed

doi:10.32553/jbpr.v10i2.859

Amro .B .E . Bashir Department of Hematology and Immunohematology, College of Medical Laboratory Science, Karary University, Khartoum, Sudan.
Tarig A.M. Hamid Department of Hematology and Immunohematology, Sharq El Niel Collage, Khartoum, Sudan.
Nadia M. Madani Department of Hematology and Immunohematology, College of Medical Laboratory Science, Karary University, Khartoum, Sudan.
Babeker Ahmed Mohammed Faculty of Medicine Department of Pathology, Karary University, Khartoum, Sudan.

DOI: https://doi.org/10.32553/jbpr.v10i2.859

Keywords: Acute Myeloid Leukemia, CD123

Abstract

Background: Acute myeloid leukemia (AML) is a heterogeneous clonal disorder characterized by immature myeloid cell proliferation and bone marrow failure. This study was prospective study conducted in Khartoum state during period from October 2018 until 2021

Objective: This study was aimed to determine the significance of the expression of CD123 in Sudanese Patients with Acute Myeloid Leukemia, and their clinical impact.

Method: The study population was selected as 100 AML patients as study group. 2.5 ml of venous blood were collected and poured into ethylene di-amine tetra acidic acid (EDTA) for examination of peripheral Blood smears and complete blood count, aspirate and trephine biopsy of bone marrow were collected for smearing and staining and detected CD markers by using flow cytometry

Results: The result showed that 57.6% of AML patients with positive CD123. The study was revealed insignificant difference in CD123 in correlated to age with p.value=0.509, and also insignificant difference in CD123 when correlated to gender male and female with p.value=0.705, and the result showed that CD123 expression was significant decreased in bone marrow sample compared to peripheral sample with p.value=0.019, also the finding showed that CD123 expression was strongest being in M3 subtype (56.8+36.8) with P-value (0.099).

Conclusion: This study was concluded that 57.6% of AML patients were positive for CD123 and also reflect thatCD123 expression was strongest being in M3 subtype.

Keyword: Acute Myeloid Leukemia, CD123 ,Sudan .